Variant · Other
ERCC4 Mutation
CI-VAR-00002835Explore in graph →CIViC 5320
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37626083
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma1 | ||||||||
| ERCC2 Mutation OR ERCC3 Mutation OR ERCC4 Mutation OR ERCC5 Mutation | Immune Checkpoint Inhibitor | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12647In a retrospective pan-cancer ICI-treated cohort from MSKCC (cohort 3, n = 1661), ERCC2/ERCC3/ERCC4/ERCC5-mutated tumors demonstrated improved OS vs ERCC-WT tumors (HR 0.54, 95% CI 0.42-0.70; p < 0.00… (full text at CIViC) PMID 37626083 · Chen et al., 2023 · Open in CIViC | civic |
| Malignant Neoplasm1 | ||||||||
| ERCC2 Mutation OR ERCC3 Mutation OR ERCC4 Mutation OR ERCC5 Mutation | (prognostic) | Prognostic | B | Supports Better Outcome | 2 | submitted | EID12645In two independent retrospective pan-cancer cohorts without ICI treatment (TCGA cohort 1 n = 3292; MSK-MET cohort 2 n = 25,659), tumors harboring ERCC2/ERCC3/ERCC4/ERCC5 mutations showed improved OS v… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available